96. クローン病
[臨床試験数:2,209,薬物数:1,276(DrugBank:240),標的遺伝子数:166,標的パスウェイ数:210

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01765439
(ClinicalTrials.gov)
February 20147/1/2013The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel DiseaseThe Effect of VSL#3 (Original De Simone Formulation) Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel DiseaseCrohn Disease;Ulcerative ColitisDietary Supplement: VSL#3 (Original De Simone formulation)Charles University, Czech RepublicIscare i.v.f., Czech Republic;CD Investments srl;University Of Perugia;University of Roma La SapienzaActive, not recruitingN/AN/AAll79N/ACzechia;Czech Republic
2NCT01632462
(ClinicalTrials.gov)
September 201225/6/2012A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's DiseaseA Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's DiseaseCrohn's DiseaseDrug: VSL#3Federico II UniversityNULLRecruiting5 Years17 YearsBoth30Phase 4Italy
3NCT01548014
(ClinicalTrials.gov)
January 201017/2/2012The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's DiseaseReduction in Frequency of Infliximab Administration From q 8 Weeks to q 12 Weeks in Children With Crohn's Disease Receiving Probiotic VSL#3 Supplementation: A Pilot StudyCrohn's DiseaseDietary Supplement: VSL#3Samsung Medical CenterNULLRecruiting13 Years17 YearsBoth1Phase 3Korea, Republic of
4NCT00367705
(ClinicalTrials.gov)
August 200922/8/2006VSL#3 Treatment in Children With Crohn's DiseaseDouble-blind Placebo Controlled Trial of VSL#3 in Children With Crohn's DiseaseCrohn's DiseaseDietary Supplement: VSL#3®;Dietary Supplement: PlaceboHadassah Medical OrganizationNULLNot yet recruiting6 Years18 YearsBoth300Phase 4Israel
5NCT00944736
(ClinicalTrials.gov)
July 200922/7/2009Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's DiseaseEffect of Probiotic VSL#3 on Intestinal Permeability of Pediatric Patients With Crohn's Disease in RemissionCrohn's DiseaseDietary Supplement: VSL#3;Dietary Supplement: PlaceboChildren's Mercy Hospital Kansas CityVSL PharmaceuticalsCompleted11 Years17 YearsBoth12Phase 3United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00114465
(ClinicalTrials.gov)
June 200514/6/2005VSL#3 Versus Placebo in Maintenance of Remission in Crohn's DiseaseRandomized, Double-Blind, Placebo-Controlled Study of VSL#3 Versus Placebo in the Maintenance of Remission in Crohn's DiseaseCrohn's DiseaseDrug: VSL#3;Other: PlaceboOrphan AustraliaNULLCompleted18 Years75 YearsBoth38Phase 4Australia
7NCT00175292
(ClinicalTrials.gov)
December 200313/9/2005A Randomized Controlled Trial of VSL#3 for the Prevention of Endoscopic Recurrence Following Surgery for Crohn's Disease.A Randomized and Placebo-Controlled Double-Blind Multicentre Study to Determine the Efficacy and Safety of VSL#3 Probiotic Food Supplement Mixture in Prevention of Endoscopic Recurrence in Crohn's Disease Patients With Ileocolonic Surgical Resection and Small Intestine to Colon Anastomosis.Crohn's Disease;Inflammatory Bowel DiseaseDrug: Probiotic - VSL#3University of AlbertaCanadian Institutes of Health Research (CIHR)Completed16 YearsN/ABoth120Phase 3Canada